跳至主要内容
临床试验/DRKS00017414
DRKS00017414招募中不适用

ong term efficacy and safety of tenofovir alafenamide fumarate (TAF) in patients with chronic hepatitis B virus(HBV) infections: an observational, non-interventional trial (TOUGH trial) - TOUGH

niversitätsklinikum Leipzig0 个研究点目标入组 200 人开始时间: 2019年9月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Chronic HBV infection diagnosed at least 6 months prior to inclusion in trial (HBsAg positive > 6 months)
  • 2. Patients receiving newly initiated treatment with TAF or
  • 3. Treatment experienced patients who switch from ongoing antiviral treatment to TAF
  • 3. Age = 18 years
  • 4. Signed informed consent form

排除标准

  • 1. Patients who are not willing or able to sign informed consent.
  • 2. Patients with HBV/HIV or HBV/HCV or HBV/HDV coinfection

研究者

发起方
niversitätsklinikum Leipzig

相似试验